Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets

1 Mar 2025

Abstract excerpt

PURPOSE Chondrosarcomas are rare cancers of cartilage with limited systemic therapy options. To identify potential therapeutic targets, this study investigated the molecular and immune landscape of three chondrosarcoma subtypes using a large database of clinical-grade sequencing results. METHODS Deidentified records from patients with a histologic diagnosis of conventional, dedifferentiated, or mesenchymal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Tumor Diagnosis and Treatments
Share to Musculoskeletal synovial abnormalities and treatments
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40117529
DOI: 10.1200/po-24-00592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic TargetsPMID 40117529Read ↗

Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.Semantic proximity Read ↗

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.Semantic proximity Read ↗

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma.Semantic proximity Read ↗

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade ChondrosarcomaSemantic proximity Read ↗

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read ↗

Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.Semantic proximity Read ↗

Chondrosarcoma: biology, genetics, and epigeneticsSemantic proximity Read ↗

Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision MedicineSemantic proximity Read ↗

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.Semantic proximity Read ↗

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?Semantic proximity Read ↗

Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to ImmunophenotypeSemantic proximity Read ↗

Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.